-
Original Article
-
Korean J Obstet Gynecol. 2006;49(10):2120-2127. Published online October 1, 2006.
- Time Trend of Survival and Treatment Modalities of Endometrial Cancer in Korea (1990-2005).
-
Kyung Jin Min, Seung Hun Song, Jae Kwan Lee, Nak Woo Lee, Jae Sung Kang, Gyu Wan Lee, Ki Sung Ryu, Byung Gie Kim, Chong Taik Park, Hee Sug Ryu, Young Tae Kim, Seung Chul Kim, Ho Sun Choi, In Ho Kim, Ho Suk Saw
-
1Department of Obstetrics and Gynecology, Korea University Medical Center, Korea. sawhs@korea.ac.kr
2Department of Obstetrics and Gynecology, The Catholic University of Korea, Korea.
3Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea.
4Department of Obstetrics and Gynecology, Samsung Cheil Hospital & Women's Healthcare Center, Sungkyunkwan University School of Medicine, Korea.
5Department of Obstetrics and Gynecology, Ajou University College of Medicine, Korea.
6Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Korea.
7Department of Obstetrics and Gynecology, Ewha Medical College, Korea.
8Department of Obstetrics and Gynecology, Collage of Medicine, Chonnam National University, Korea.
9Department of Obstetrics and Gynecology, Pundang CHA Hospital, College of Medicine Pochon CHA University, Korea.
- Abstract
- OBJECTIVE
This study was performed to evaluate the overall survival and the change in treatment modalities in patients with uterine endometrial cancer in Korea. METHODS: From January 1990 to March 2005, medical records of 740 patients with endometrial cancer in nine hospitals were reviewed. The overall survival was determined supported by the death statistics of Korea National Statistical Office. RESULTS: The mean age of patients was 51.5 years (range: 21-82 years). The mean gravidity and parity were 3.3 and 2.1 (range: 0-18, 0-9), respectively. The most common stage, grade and histological type at diagnosis were FIGO stage I, grade 1 and endometrioid adenocarcinoma (76.5%, 56.4% and 87.2%), respectively. The main treatment modalities was surgery on stage I (59.8%), surgery-adjuvant radiotherapy on stage II (55.1%), surgery-adjuvant radiotherapy or surgery-adjuvant chemoradiation on stage III (38.3%) and surgery-adjuvant chemotherapy on stage IV (55.6%). The preferred treatment modality was surgery only on grade 1 (69.0%) and surgery-adjuvant radiotherapy on grade 2-3 (43.4% and 53.2%). Surgery had been the most common method of therapy before 1998 but its prevalence gradually decreased. As a result, surgery-adjuvant radiotherapy and surgery-adjuvant chemotherapy were most widely performed in 2004-2005 and surgery-adjuvant chemoradiation also increased more than a twofold. The overall 5 years survival rate (5YSR) for all 740 patients was 81.3%. The overall 5YSR of stage I was 89.0%. The overall 5YSR of grade 1, grade 2, grade 3 were 96.0%, 92.0%, 80.0%. Before 1998, the survival rate was 77.0%. Since then it increased to 83-88% and in 2000-2001 it increased to 88.0%, and it was the highest survival rate. CONCLUSION: The survival rate of endometrial cancer has been improving for the past 15 years and the method of treatment is also being changed currently. In order to improve the survival rate of endometrial cancer, a close investigation including genetic and environmental factors of the pathophysiology of endometrial cancer along with the epidemiology of risk factors, should be carried out.
Keywords :Endometrial cancer;Survival;Treatment modality
